Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Market: LSE:RENE
52-week High/Low: 220.00p / 1.95p
Sector: Pharma & Biotech
Market Cap: 28.64M
ReNeuron Group Plc (:RENE)

ReNeuron Group Plc

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron Group Plc

Interactive graph

col 3
col 4
col 5
col 6

ReNeuron Group Plc RNS Announcements

Date Epic Announcement
31/07/2018 RENE Posting of Annual Report & Notice of AGM
17/07/2018 RENE Notification of Major Holdings
16/07/2018 RENE Notification of Major Holdings
16/07/2018 RENE Notification of Major Holdings
13/07/2018 RENE Notification of Major Holdings
12/07/2018 RENE Preliminary Results
11/07/2018 RENE Signs retinal stem cell exclusivity agreement
04/07/2018 RENE Notification of Preliminary Results
17/05/2018 RENE Capital Markets Event
04/05/2018 RENE Exosome data presented at ISCT conference
30/04/2018 RENE Capital Markets Event and Webcast
19/04/2018 RENE Wins grant for retinal cell therapy development
10/04/2018 RENE Appointment of US-based Chief Medical Officer
26/03/2018 RENE Product Development Update
01/03/2018 RENE Block Listing Review and TVR
16/02/2018 RENE Block Listing Application
13/02/2018 RENE Positive pre-clinical data in nerve injury
26/01/2018 RENE Phase II stroke data presented at AHA conference
23/01/2018 RENE Approval of Share Capital Reorganisation
11/01/2018 RENE Further re Share Capital Reorganisation
05/01/2018 RENE Proposed Share Capital Reorganisation
14/12/2017 RENE Interim results
14/12/2017 RENE Stroke clinical trial regulatory approval in US
08/12/2017 RENE ReNeuron opens US office
13/11/2017 RENE Notification of Interim Results
08/11/2017 RENE Retinal disease clinical trial moves into Phase II
31/10/2017 RENE Positive stroke clinical data & regulatory update
27/10/2017 RENE Wins further UK grant
11/10/2017 RENE PDMR Interest in Shares and Share Options
09/10/2017 RENE Presentation of positive pre-clinical data

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use